Rheumatoid arthritis treatment in patients with a history of cancer.
What is the best treatment option in patients with active rheumatoid arthritis who have a history of malignant disease? Rheumatologists are increasingly faced with this question in their daily practice. As uncontrolled high disease activity is an important risk factor for further comorbidities and shortened life expectancy, the treatment has to be effective, without bearing a higher risk for cancer recurrence. What data is available today to guide treatment decisions and how robust is its evidence? As patients with prior cancer are usually not included in randomized controlled trials, all data we have to elucidate this topic stems from observational cohort studies, mainly biologics registers established in several European countries. The registries investigated the risk of recurrence of cancer mainly by comparing treatments with csDMARDs and TNF inhibitors. Few results are available so far for the treatment with rituximab. However, because of their observational design, the data can only reflect current clinical practice. Because of the lack of evidence, questions such as: are biologics soon after cancer diagnosis safe, remain. There is still insufficient data for patients with a very recent history of cancer. However, in patients with cancer being in longer remission, observational data suggest no increased risk of overall cancer recurrence when they are treated either with TNF inhibitors or rituximab.